Japanese pharma company Nippon Shinyaku (TYO: 4516) and privately-held UK small activating RNA (RNAa) therapeutics specialist MiNA Therapeutics have announced a collaboration.
The companies have entered into a joint research agreement with the aim of creating nucleic acid medicines that are expected to be applied to an intractable and rare disease in the central nervous system field.
MiNA will provide Nippon Shinyaku with RNAa therapeutics, which are oligonucleotides that can increase the transcription of a target gene.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze